Citation: Sunhwangi. 49(8):645-656, 2019 Aug..Journal: Korean circulation journal.Published: ; 2019ISSN: 1738-5520.Full author list: Shlofmitz E; Shlofmitz R; Lee MS.UI/PMID: 31347321.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal Article | ReviewOnline resources: Click here to access onlineDigital Object Identifier: https://dx.doi.org/10.4070/kcj.2019.0185 (Click here)ORCID: Shlofmitz, Evan https://orcid.org/0000-0002-0907-5258 (Click here)Abbreviated citation: Korean circ. j.. 49(8):645-656, 2019 Aug.Abstract: The number of patients undergoing percutaneous coronary intervention (PCI) who mandate additional oral anticoagulant therapy has been increasing. Dual antiplatelet therapy (DAPT) is associated with reduced ischemic events including stent thrombosis, myocardial infarction and stroke following PCI. However, the tradeoff is an increased risk for bleeding while on DAPT. The addition of a novel oral anticoagulant (NOAC) further increases the likelihood of bleeding while on antiplatelet therapy. Thus, the overall risks and benefits for each patient undergoing PCI on NOAC must be assessed and therapy individualized to ensure optimal therapy for each unique situation. Patients on NOAC undergoing PCI should undergo routine assessment with intravascular imaging as the role of high-risk lesion-related features have increased importance prior to determining optimal duration of treatment with DAPT. We review the best practices for the pharmacologic management of patients requiring anticoagulation with NOAC who are treated with PCI and require antiplatelet therapy.Abstract: Copyright (c) 2019. The Korean Society of Cardiology.